This inventor holds 2 USPTO granted patents. Top assignees: Spofa, Spojene Podniky Pro Zdravotnickou Vyrobu, Vufb A.s. Active years: 1988-1997.
Company Filing History:
Years Active: 1988-1997
Title: Milan Miko: Innovator in Antitumor Drug Development
Introduction
Milan Miko is a notable inventor based in Bratislava, Slovakia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumor compounds. With a total of 2 patents, his work has the potential to impact the treatment of malignant neoplasias in mammals.
Latest Patents
Milan Miko's latest patents include innovative compounds such as 6-[X-(2-hydroxyethyl)aminoalkyl]-5,11-dioxo-5,6-dihydro-11H-indeno[-1,2-c]isochinoline derivatives. These compounds are characterized by a general formula where X represents the number of carbon atoms from 0 to 5 in the aminoalkyl group. The preparation of these antitumor compounds involves reacting indeno[1,2-c]isocoumarine with N-(hydroxyethyl)alkylen diamine in a suitable aprotic solvent, preferably dimethylformamide, at elevated temperatures. Another notable process includes the reaction of 6-(X-chloroalkyl)-5,11-dioxo-5,6-dihydro-11H-indeno[1,2-c]isochinolines with 2-aminoethanol, also in dimethylformamide, in the presence of anhydrous potassium carbonate. These compounds demonstrate remarkable antineoplastic effects, showcasing their potential for drug development.
Career Highlights
Throughout his career, Milan Miko has worked with various companies, including Vufb A.s and Spofa, Spojene Podniky Pro Zdravotnickou Vyrobu. His expertise in the pharmaceutical field has allowed him to contribute to significant advancements in drug formulation and development.
Collaborations
Milan Miko has collaborated with notable professionals in his field, including Jiri Krepelka and Milan Melka. These collaborations have further enriched his research and development efforts.
Conclusion
Milan Miko's innovative work in the development of antitumor compounds positions him as a key figure in pharmaceutical research. His contributions have the potential to lead to significant advancements in the treatment of cancer.